Northwire Canada EditionWednesday, July 15, 2026
Northwire
EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0% EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0%
Financings

Onco-Innovations lowers per-unit price of placement

ONCO · Price

Executive Summary

  • Onco‑Innovations Ltd. amended its previously announced non‑brokered private placement, increasing the offering size to up to 3,076,923 units at $0.65 per unit for gross proceeds of up to $2 million.
  • Each unit consists of one common share and one warrant exercisable at $0.75 per share for three years; an additional 1 % of the issued shares will be allocated as an administrative fee to a third‑party facilitator.
  • Proceeds are earmarked for general corporate and working capital purposes, including operational, R&D, and investor‑relations activities.

Key Details

  • Units Offered: Up to 3,076,923 units (each unit = 1 common share + 1 warrant).
  • Price per Unit: $0.65.
  • Aggregate Gross Proceeds: Up to $2 million.
  • Warrant Terms: Each warrant allows purchase of one share at $0.75, exercisable for three years from issuance.
  • Administrative Fee Shares: 1.0 % of the total shares issued will be granted to an arm’s‑length third party as compensation for assistance with the placement.
  • Finder’s Fees/Warrants: Company may issue additional finders’ fees or warrants on the same terms to parties introducing subscribers.
  • Closing Conditions: Subject to receipt of all required regulatory and other approvals; securities will be subject to a hold period of four months and one day.
  • Use of Proceeds: General corporate and working‑capital purposes, including pursuit of operational objectives, research & development initiatives, and investor‑relations activities.

Notable Quotes

(No executive quotes were provided in the release.)

Read the original news release →

More from Onco-Innovations Ltd